REDMOND, WA, May 24, 2022 — Pattern Computer®, Inc. (PCI) is pleased to announce the advancement of our potential combination therapy candidates against High-grade Serous Ovarian cancer beyond the first stage of in vitro studies. In both cases, the drugs showed combined synergy against targeted cancer cells.
These results are preliminary, in the sense that the larger test suite is yet to be completed. In all, PCI has designed 31 combination therapy candidates in this series of tests against three different cell lines; the current announcement comes after the first cell line tests have been completed. It is possible that additional drugs will also emerge from this test suite showing synergy against additional tissue lines of Ovarian cancer.
The work is being done at a nationally-recognized clinical testing organization.
PCI’s drug discovery efforts are currently focused on oncological malignancies. Using our innovative Pattern Discovery Engine™ (PDE), we have already identified and have under preclinical development, two sets of potential combination therapies for triple-negative Breast cancer (TNBC), the most difficult to treat and most aggressive subtype of breast cancer. Our capability for discovering polythetic patterns of interacting genes in genomics data is only made possible by the PDE. In addition, we are actively and aggressively applying this to other complex and intractable cancers including High-grade Serous Ovarian Cancer, and metastatic Castration-Resistant Prostate Cancer (mCRPC).
“We are excited to be able to announce that we now have doubled our oncology drug discovery pipeline from two to four candidates, in both breast and ovarian cancers. We look forward to getting the final results on the other two Ovarian cell line tests, for all 31 new candidates, and will keep our friends and investors posted on these results as they come in. We feel that this second round of current outcomes go a long way toward providing solid evidence that our Pattern Discovery Engines are capable of rapid and accurate drug discovery using mathematics and techniques which are demonstrably more effective than those used previously,” said Mark Anderson, CEO, Pattern Computer.
“And, as part of our larger StarBright Project, this announcement represents moving forward in just two of the five cancer killers we are working on today. We will be making additional announcements shortly on new discoveries in metastatic Castration-Resistant Prostate Cancer (mCRPC), Lung Cancer and Colorectal Cancer. The whole team is very excited and proud regarding the speed and accuracy to date of these very early steps. As an example, we were able to identify new genetic discoveries in the computational phase of the Ovarian cancer work in just six weeks.
“By making a positive difference in TPN Breast Cancer, Serous Ovarian Cancer, Lung Cancer, Colorectal Cancer, and Metastatic Castration-Resistant Prostate Cancer, we hope to show that this new Pattern Discovery Engine approach to medicine will indeed be disruptive, both in making major steps forward in oncology and other fields, and in moving far beyond the results of yesterday’s mathematical tools,” Anderson added.
About Pattern Computer
Pattern Computer, Inc., a Seattle-area firm, uses its proprietary Pattern Discovery Engine™ to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.
While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including COVID detection, biomedical research, resource extraction, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.
CONTACT: Brad Holtz – 301.529.9944 – bh@patterncomputer.com
The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.
Copyright © 2022 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, Dimensional Navigator, and ProSpectral are trademarks of Pattern Computer, Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.